Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from Analysts at HC Wainwright

Equities researchers at HC Wainwright assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report issued on Monday, MarketBeat reports. The firm set a “sell” rating and a $80.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential downside of 38.70% from the company’s previous close.

SRPT has been the topic of a number of other research reports. Guggenheim boosted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. UBS Group boosted their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Robert W. Baird dropped their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $176.73.

Sarepta Therapeutics Price Performance

SRPT stock opened at $130.50 on Monday. The firm’s 50-day moving average price is $121.80 and its two-hundred day moving average price is $131.40. Sarepta Therapeutics has a 12-month low of $78.67 and a 12-month high of $173.25. The stock has a market capitalization of $12.47 billion, a price-to-earnings ratio of 104.40 and a beta of 0.81. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Fifth Third Wealth Advisors LLC bought a new position in shares of Sarepta Therapeutics during the second quarter worth $607,000. Teachers Retirement System of The State of Kentucky purchased a new position in Sarepta Therapeutics in the 2nd quarter worth about $4,771,000. Simplify Asset Management Inc. increased its stake in Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after buying an additional 88,474 shares during the period. Securian Asset Management Inc. purchased a new position in Sarepta Therapeutics in the 2nd quarter worth about $1,187,000. Finally, Natixis Advisors LLC purchased a new position in Sarepta Therapeutics in the 2nd quarter worth about $1,918,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.